skip to main content

MET Exon 14 NSCLC — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardLung CancerMET Exon 14 NSCLCSCE Medical Oncology

A patient in England has advanced NSCLC with a confirmed MET exon 14 skipping alteration and has not previously received a MET inhibitor. Which statement most accurately reflects current routine NICE access?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Tepotinib is a recommended selective MET-inhibitor option under NICE TA789

NICE TA789 recommends tepotinib within its marketing authorisation and commercial arrangement for advanced METex14-skipping NSCLC. The capmatinib NICE appraisal was terminated and TA884 therefore does not recommend it. Crizotinib is not the current NICE METex14 recommendation. Savolitinib has no such NICE recommendation. TA789 does not impose mandatory failure of both immunotherapy and docetaxel before access.

Reference: NICE TA789 tepotinib for advanced NSCLC with MET exon 14 skipping (Published May 2022; current NICE TA): https://www.nice.org.uk/guidance/ta789/chapter/1-Recommendations